Prospective post-marketing surveillance study of Prevenar [pneumococcal 7 valent CRM197 vaccine conjugate] in high-risk children aged 2 to 5 years
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2007
At a glance
- Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Wyeth
- 07 Dec 2007 Status change from in progress to completed.
- 25 May 2007 Status changed from recruiting to in progress.
- 31 Aug 2006 New trial record.